Multicenter comparison of the diagnostic performance of free prostate- specific antigen

Urology

Volumn 48, Issue 6 SUPPL., 1996, Pages 45-50

  Thiel, Robert P ^a   Oesterling, Joseph E ^b,c   Wojno, Kirk J ^c   Partin, Alan W ^d,e   Chan, Daniel W ^e   Carter, H Ballentine ^d,e   Stamey, Thomas A ^f   Prestigiacomo, Anthony R ^f   Brawer, Michael K ^g   Petteway, Jason C ^g   Carlson, Grant ^a   Luderer, Albert A ^a  

^a Dianon Systems   (United States)

^b Michigan Prostate Institute   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d Brady Urological Institute   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

^f STANFORD UNIVERSITY   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER RISK; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY;

ADULT; AGED; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0030460436     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00609-7     Document Type: Article

References (11)

1. Wang MC, Valenzuela LA, Murphy GP, and Chu TM: Purification of a human prostate-specific antigen. Invest Urol 17: 159-163, 1979.
2. Christensson A, Laurell CB, and Lilja H: Enzymatic activity of prostate-specific antigen and its reaction with extracellular serine proteinase inhibitors. Eur J Biochem 194: 755-763, 1990.
3. 1-antichymotrypsin. Clin Chem 37: 1618-1625, 1991.
4. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
5. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 150: 100-105, 1993.
6. Luderer AA, Chen YT, Soriano TF, Kramp WJ, Carlson G, Cuny CL, Sharp T, Smith W, Petteway J, Brawer MK, and Thiel RP: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of prostate-specific antigen. Urology 46: 187-194, 1995.
7. Chen YT, Luderer AA, Thiel RP, Carlson G, Cuney CL, and Soriano TF: Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology 47: 518-524, 1996.
8. Passing H, Bablok W, and Glocke M: An optimal design for the establishment of assigned values in control sera. The establishment of assigned values in control sera, IV.J Clin Chem Clin Biochem 19: 1167-1179, 1981.
9. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, and Nadler RB. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
10. Yemoto CM, Nolley R, Prestigiacomo AF, and Stamey TA: Free (f) and total (t) PSA density in patients with prostate cancer (CaP) and benign prostatic hyperplasia (BPH). J Urol 155: 374A, 1996.
11. Oesterling JE, Jacobson SJ, Chute CG, Guess HA, Girman CJ, Panser LA, and Leiber MM: Serum prostate-specific antigen in a community based population of healthy men. Establishment of age specific reference ranges. JAMA 270: 860-864, 1993.